npj Parkinson s DiseaseGenetic & Genomic MedicinePeer-reviewed journal article
Fine mapping of the HLA locus in Parkinson's disease in Europeans
Eric YuiD, Aditya AmbatiiD, Maren Stolp Andersen, Lynne KrohniD, Mehrdad A. EstiariD, Prabhjyot Saini, Konstantin A. SenkevichiD, Yuri Ludwig SoseroiD, Ashwin Ashok Kumar SreelathaiD, Jennifer A. RuskeyiD, Farnaz AsayeshiD, Dan SpiegelmaniD, Mathias ToftiD, Marte Kathrine VikeniD, Manu SharmaiD, Cornelis BlauwendraatiD, Lasse PihlstrømiD, Emmanuel Jean-Marie MignotiD, Ziv Gan‐OriD
Abstract
ObjectiveTo fine map the association between human leukocyte antigen (HLA) genes and Parkinsons disease (PD) that was discovered using genome-wide association studies (GWASs). MethodsWe performed a thorough analysis of the HLA locus in 13,770 PD patients, 20,214 proxy-cases and 490,861 controls of European origin. We used GWAS data to impute HLA types and performed multiple regression models to examine the association of specific HLA types, different haplotypes and specific amino acid changes. We further performed conditional analyzes to identify specific alleles or genetic variants that drive the association with PD. ResultsFour HLA types were associated with PD after correction for multiple comparisons, HLA-DQA1*03:01, HLA-DQB1*03:02, HLA-DRB1*04:01 and HLA-DRB1*04:04. Haplotype analyzes followed by amino-acid analysis and conditional analyzes suggested that the association is protective and primarily driven by three specific amino acid polymorphisms present in most HLA-DRB1*04 subtypes - 11V, 13H and 33H (OR=0.87 95%CI=0.83-0.90, p<8.23x10-9 for all three variants). No other effects were present after adjustment for these amino acids. ConclusionsOur results suggest that specific variants in the HLA-DRB1 gene are associated with reduced risk of PD, providing additional evidence for the role of the immune system in PD. Although effect size is small and has no diagnostic significance, understanding the mechanism underlying this association may lead to identification of new targets for therapeutics development.
- organism: human
- assay: GWAS summary statistics
- research focus: fine-mapping
- approach: statistical model
- Citations
- 71
- FWCI
- 5.91
- Field percentile
- top 3%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exploring MAPT-containing H1 and H2 haplotypes in Parkinson's disease across diverse populations
Paula Reyes‐Pérez, Jia Wei Hor, … Álvaro Hernandez-Guillen·npj Parkinson s DiseasePeer-reviewed·Jun 24, 2026
- 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinsons disease are associated with LRRC37A/2 expression in astrocytes
Kathryn R. Bowles, Derian A. Pugh, … Alison Goate·Molecular NeurodegenerationPeer-reviewed·Jul 15, 2022
- Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease
Yuri Ludwig Sosero, Sara Bandrés‐Ciga, … Lynne Krohn·Neurobiology of AgingPeer-reviewed·Nov 1, 2021
- Insights Into Parkinsons Disease Genetics in African Populations: Expanded GWAS Identifies Ancestry-Specific and Cross-Population Risk Loci
N. Okubadejo, O. O. Ojo, … Asli·medRxiv·Mar 3, 2026
- Ancestry-specific immune signatures in Parkinson's disease: a rare variant burden analysis in Montreal and Guadeloupe cohorts
Lovatiana Andriamboavonjy, Marjorie Labrecque, … Martine Tétreault·medRxiv·May 4, 2026
- Common and rare variants in HFE are not associated with Parkinson's disease in Europeans
Prabhjyot Saini, Sara Bandrés‐Ciga, … Ziv Gan‐Or·Neurobiology of AgingPeer-reviewed·Jun 8, 2021